Rate My Professor Nicholas Wilcken

Throughout his career, Wilcken has held prominent positions in clinical oncology and academia. He currently directs the Medical Oncology service at the Crown Princess Mary Cancer Centre, Westmead Hospital, and serves as Senior Staff Specialist at Nepean Cancer Care Centre. His academic and research interests centre on breast cancer, with a strong emphasis on clinical trials and systematic reviews of treatment efficacy. Notable contributions include serving as Co-ordinating Editor for the Cochrane Breast Cancer Group, membership on the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) in Oxford, UK, and participation as an invited expert panel member at multiple St Gallen International Consensus Conferences on Early Breast Cancer.

Wilcken has authored or co-authored influential publications, including the Cochrane review "Taxanes for adjuvant treatment of early breast cancer" (2019), "Ovarian suppression in premenopausal women with hormone-receptor positive early breast cancer" (2007), "Dose Escalation of Tamoxifen in Patients with Low Endoxifen Levels" (Clinical Cancer Research, 2016), and "Systemic treatment of HER2-positive metastatic breast cancer" (Asia-Pacific Journal of Clinical Oncology, 2014). Within Australia, he chaired the Scientific Advisory Committee of Breast Cancer Trials from 2011 to 2017 and joined its Board of Directors in 2016. These roles underscore his impact on shaping evidence-based practices in breast cancer management through rigorous research and international collaboration.